tiprankstipranks
Trending News
More News >
Advertisement
Advertisement
Immatics Presents Promising IMA203 Data at ASCO 2025
PremiumCompany AnnouncementsImmatics Presents Promising IMA203 Data at ASCO 2025
3M ago
Immatics announces presentation of data from ongoing Phase 1b trial on IMA203
Premium
The Fly
Immatics announces presentation of data from ongoing Phase 1b trial on IMA203
3M ago
Immatics initiated with a Buy at Deutsche Bank
Premium
The Fly
Immatics initiated with a Buy at Deutsche Bank
3M ago
Immatics Reports Strong 2024 Financial Results and Progress
PremiumCompany AnnouncementsImmatics Reports Strong 2024 Financial Results and Progress
5M ago
Immatics files $500M mixed securities shelf
Premium
The Fly
Immatics files $500M mixed securities shelf
5M ago
Immatics Advances Cancer Immunotherapy with Phase 3 Trial and Strong Financials
Premium
Company Announcements
Immatics Advances Cancer Immunotherapy with Phase 3 Trial and Strong Financials
5M ago
Immatics N.V. Reports Strong Q3 2024 Progress and Financials
PremiumCompany AnnouncementsImmatics N.V. Reports Strong Q3 2024 Progress and Financials
9M ago
Immatics moved to Buy from Not Rated at Goldman Sachs
Premium
The Fly
Immatics moved to Buy from Not Rated at Goldman Sachs
9M ago
Immatics price target lowered to $15 from $16 at BofA
Premium
The Fly
Immatics price target lowered to $15 from $16 at BofA
9M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100